Merck, S.L., Spain
11
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
27.3%
3 terminated/withdrawn out of 11 trials
66.7%
-19.8% vs industry average
36%
4 trials in Phase 3/4
67%
4 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
PErsonalized Addition of Recombinant LH in Ovarian Stimulation
Role: collaborator
Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer
Role: collaborator
Recombinant LH Prior to Ovarian Stimulation in Poor Ovarian Responders (PRE-LH)
Role: collaborator
Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma
Role: collaborator
Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone
Role: collaborator
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Spain
Role: collaborator
Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
Role: collaborator
A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age
Role: collaborator
A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age
Role: collaborator
Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets
Role: collaborator
Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome
Role: collaborator
All 11 trials loaded